Comparison of Chemotherapy vs Chemotherapy Plus Total Hysterectomy for Women With Uterine Cancer With Distant Organ Metastasis
Menée à partir de données américaines 2010-2014 portant sur 3 197 patientes atteintes d'un cancer de l'utérus et présentant des métastases à distance (âge moyen : 61,9 ans ; durée médiane de suivi : 13,4 mois), cette étude analyse l'intérêt, du point de vue de la survie globale, d'associer une hystérectomie abdominale totale à la chimiothérapie
Uterine cancer is the most common gynecologic cancer, and 9% of patients have metastatic disease at initial presentation.1 In addition to systemic therapy, total abdominal hysterectomy (TAH) with maximal cytoreduction has been shown to increase survival for patients with abdominal or pelvic metastases.1-3 However, to our knowledge, the role of TAH for uterine cancer with distant organ metastasis has not been established. In addition, there is growing evidence that definitive local therapies may increase survival for some types of metastatic cancers.4-6 In this cohort study, we evaluate the overall survival for patients with uterine cancer with distant organ metastasis treated with chemotherapy alone vs chemotherapy plus TAH.